Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
All content for On The Pen With Dave Knapp is the property of Bleav, Dave Knapp Founder of On The Pen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
This week’s On The Pen podcast unpacked major developments in obesity and metabolic health. New data from Harvard and Mass General suggest that nearly 70% of U.S. adults may qualify as having obesity when waist circumference is added to BMI. Dave also covered an emerging oral triple agonist with breakthrough absorption rates, promising early results from Fractal Health showing weight maintenance after GLP-1 discontinuation, and recent cash-pay price reductions for Zepbound. The episode also revisited Novo Nordisk’s Alzheimer’s trial, clarifying why the results weren’t the final word on GLP-1s in cognitive disease. Dave closed with personal insights on hunger signals after switching medications, plus updates on access, tools, and upcoming savings programs.
On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
